UNIVERSITY OF ALABAMA AT BIRMINGHAM

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1969-01-01

Employees: 2K

Market Cap: -

Website: http://www.uab.edu

Clinical Trials

CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Breast Cancer
Colorectal Cancer
Lung Cancer
Pancreatic Cancer

First Posted Date: 2003-07-08

Last Posted Date: 2013-04-12

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT00033384

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2003-06-06

Last Posted Date: 2015-10-08

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT00062270

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

AG2037 in Treating Patients With Advanced, Metastatic, or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-16

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 22

Registration Number: NCT00017524

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy

Phase 1

Conditions: Head and Neck Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-04

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT00004226

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
Veterans Affairs Medical Center - Tampa (Haley), Tampa, Florida, United States

Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx

Phase 3

Terminated

Conditions: Head and Neck Cancer

Interventions: Procedure: conventional surgery
Biological: cetuximab
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-06

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 32

Registration Number: NCT00004227

Locations: 🇺🇸
Monmouth Medical Center, Long Branch, New Jersey, United States
🇺🇸
ImClone Systems, Incorporated, Somerville, New Jersey, United States
🇺🇸
Kimball Medical Center, Lakewood, New Jersey, United States

Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Biological: rituximab
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-13

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 18

Registration Number: NCT00033423

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Stanford Comprehensive Cancer Center - Stanford, Stanford, California, United States
🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

Phase 3

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: recombinant interferon alfa
Procedure: lymphangiography
Drug: Observation

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-20

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 3000

Registration Number: NCT00004196

Locations: 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 1 locations

Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses

Phase 2

Withdrawn

Conditions: Precancerous Condition

Interventions: Drug: Placebo
Drug: celecoxib

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-05

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT00027976

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States

and more 4 locations

Family Blood Pressure Program - HyperGEN

Completed

Conditions: Heart Diseases
Hypertension
Cardiovascular Diseases

First Posted Date: 2000-05-26

Last Posted Date: 2015-10-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 3604

Registration Number: NCT00005267

Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

Phase 2

Completed

Conditions: Purpura, Thrombocytopenic, Idiopathic

First Posted Date: 2000-05-03

Last Posted Date: 2008-09-09

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 20

Registration Number: NCT00005652

Locations: 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy